Results 31 to 40 of about 216,339 (397)
Repeating platinum/bevacizumab in recurrent or progressive cervical cancer yields marginal survival benefits [PDF]
, 2017 Our objective was to assess overall survival of cervical cancer patients following prior platinum/bevacizumab chemotherapy, comparing retreatment with platinum/bevacizumab with alternative therapies.
Massad, L. Stewart +3 more
core +3 more sources
Bevacizumab in recurrent glioblastoma [PDF]
Translational Cancer Research, 2019 In May 2009, the U.S. Food and Drug Administration granted accelerated approval for the use of bevacizumab in patients with progressive glioblastoma (GBM), the most common malignant primary brain tumor in adults (1). Neovascularization is a morphologic hallmark of GBM, driven in part by vascular endothelial growth factor A (VEGF-A) which is targeted ...
Nina L. Martinez, Jon Glass, Wenyin Shi
openaire +2 more sources
Efficacy and toxicity of bevacizumab in recurrent ovarian disease: an update meta-analysis on phase III trials [PDF]
, 2015 Background: To analyze the efficacy and toxicity of bevacizumab on survival outcomes in recurrent ovarian cancer. Results: Bevacizumab was associated with significant improvement of PFS and OS compared with standard treatment with HRs of 0.53 (95% CI 0.
BENEDETTI PANICI, PIERLUIGI +9 more
core +1 more source
EXPERIENCE OF BEVACIZUMAB USE IN PATIENTS WITH INOPERABLE COLORECTAL CANCER IN KIROV REGION
Тазовая хирургия и онкология, 2015 Purpose. To conduct retrospective analysis of treatment results of combined first line therapy of metastatic colorectal cancer with bevacizumab with further bevacizumab maintenance and second line treatment with or without bevacizumab use in Kirov ...
N. Z. Sherman +2 more
doaj +1 more source
Drugs in R&D, 2023 Background BAT1706 is a proposed biosimilar of bevacizumab, a vascular endothelial growth factor A (VEGF-A)-targeting biologic used to treat several different cancers, including metastatic colorectal cancer. A comprehensive physicochemical and functional
Di Cao +9 more
doaj +1 more source
Factors influencing choice of chemotherapy in metastatic colorectal cancer (mCRC) [PDF]
, 2013 Management of metastatic colorectal cancer requires a multimodal approach and must be performed by an experienced, multidisciplinary expert team. The optimal choice of the individual treatment modality, according to disease localization and extent, tumor
BASSO, ENRICO +15 more
core +1 more source
Case Reports in Neurology, 2016 Patients with bevacizumab-refractory recurrent glioblastoma multiforme (GBM) have a poor prognosis. We propose that instead of continuing on bevacizumab, patients should switch to treatment with Optune™, a novel antimitotic Tumor-Treating Fields ...
George Ansstas, David D. Tran
doaj +1 more source
MDM Policy & Practice, 2021 Background. Real-world evidence can be a valuable tool when clinical trial data are incomplete or uncertain. Bevacizumab was adopted as first-line therapy for metastatic colorectal cancer (mCRC) based on significant survival improvements in initial ...
Reka E. Pataky +11 more
doaj +1 more source
SB8: A Bevacizumab Biosimilar [PDF]
Targeted Oncology, 2020 SB8 is a biosimilar of the monoclonal anti-VEGF antibody bevacizumab and is approved in the EU for use in the same types of cancer as bevacizumab. SB8 has similar physicochemical and pharmacodynamic properties to those of reference bevacizumab and pharmacokinetic equivalence was shown in healthy volunteers and patients with non-small cell lung cancer ...
openaire +3 more sources
Phase II trial of preoperative radiochemotherapy with concurrent bevacizumab, capecitabine and oxaliplatin in patients with locally advanced rectal cancer [PDF]
, 2013 Background: Preoperative radiochemotherapy (RCT) with 5-FU or capecitabine is the standard of care for patients with locally advanced rectal cancer (LARC). Preoperative RCT achieves pathological complete response rates (pCR) of 10-15%.
Arnold, Dirk +9 more
core +1 more source